Vision restoration therapy and raising red flags too early
- PMID: 16708417
- PMCID: PMC1857038
Vision restoration therapy and raising red flags too early
Conflict of interest statement
Competing interests: BAS is a shareholder of and consultant to NovaVision, the manufacturer of vision restoration therapy (VRT). NovaVision has also supported research studies conducted in the laboratory of BAS.
Comment on
-
Disappointing results from Nova Vision's visual restoration therapy.Br J Ophthalmol. 2005 Jan;89(1):1-2. doi: 10.1136/bjo.2004.058214. Br J Ophthalmol. 2005. PMID: 15615733 Free PMC article. No abstract available.
References
-
- Kasten E, Wuest S, Sabel B A. Residual vision in transition zones in patients with cerebral blindness. J Clin Exp Neuropsychol 199820581–598. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical